Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder

September 14, 2010 By Bio-Medicine.Org

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ — Neurocrine
Biosciences, Inc. (Nasdaq:
NBIX
) today announced top-line efficacy and safety results from
a Phase II clinical trial utilizing Corticotropin Releasing Factor
(CRF1) receptor antagonist GSK561679 in patients currently
experiencing a major depressive episode.  This double-blind,
placebo controlled trial randomized 150 patients into two treatment
arms, 350 mg of GSK561679 daily and placebo, and was conducted in
the United States by GlaxoSmithKline (GSK) under the GSK/Neurocrine
CRF1 collaboration. The primary endpoint was change from baseline
in the Bech Melancholia scale at Week 6 and a key secondary
endpoint was change from baseline in the HAMD-17 scale at Week
6.

Results of statistical analysis using the intent-to-treat
population revealed no benefit of GSK561679 compared with placebo
on both the Bech Melancholia and HAMD-17 endpoints. The
top-line results are based on the six week placebo-controlled
portion of the study for the intent to treat population of 145
patients. From a safety perspective, there were no significant
adverse events, and the drug was generally well tolerated.

“It is clear from this study that CRF1 remains a difficult drug
target in the drive to improve current pharmaceutical therapies for
depression,” said Kevin Gorman, President and Chief Executive
Officer of Neurocrine Biosciences.  “We plan to meet with GSK
in the coming months after the full clinical data set is complete
to determine the next steps for the CRF depression program.”

Three separate academic collaborative clinical trials are
ongoing to evaluate the effects of GSK561679 in Post Traumatic
Stress Disorder, anxiety and alcoholism.

Neurocrine Biosciences, Inc. is a biopharmaceutical company
focused on neurological and endocrine diseases and disorders. Our
product candidates address some of the lar

‘/>”/>

SOURCE

Related Articles Read More >

Carnegie Mellon University EEG-based BCI to control robotic hand
Non-invasive BCI enables robotic hand dexterity
How this device broke through the blood-brain barrier
A photo of the miniature Auxilium Biotechnologies implants made on the International Space Station.
Implants 3D-printed in space could enable nerve regeneration
An illustration showing the Artedrone Sasha thrombectomy catheter approaching a blood clot.
This microrobot system is designed to float inside a stroke patient for autonomous thrombectomy
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe